<DOC>
	<DOC>NCT01590615</DOC>
	<brief_summary>This registry will remain open for approximately 5 years (4 years of enrollment + 1 year of follow up). Subjects will be followed until Orthotopic Liver Transplant (OLT), resolution of liver decompensation, death, or conclusion of the registry.</brief_summary>
	<brief_title>Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>Inclusions: Estimated glomerular filtration rate (CockcroftGault method)using actual body weight of â‰¥ 50 mL/min at time of entry into registry Negative serologies for HIV, hepatitis C virus (HCV), and/or hepatitis D virus (HDV) No history of solid organ or bone marrow transplant Currently receiving or anticipated to receive antiHBV nucleoside/nucleotide therapy within 6 months of inclusion into registry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>HBV</keyword>
	<keyword>OLT</keyword>
	<keyword>MELD</keyword>
	<keyword>Renal Safety</keyword>
	<keyword>Liver Transplant</keyword>
</DOC>